Related by context. All words. (Click for frequent words.) 66 Zevalin consolidation 64 generalisability 64 empirically validated 63 Rigorous scientific 62 methodologically sound 62 ConclusionThis 62 selenium supplementation 62 Systematic reviews 61 riociguat 61 methodological weaknesses 61 multicenter trials 61 Polygraph examinations 61 surveys Herbenick 60 Meta analyzes 60 longitudinal cohort 60 oral PrEP 60 isoflavone supplement 60 correlational 60 biologic plausibility 60 IMPROVE HF 60 ACCORD Lipid 60 CAM modalities 59 prospective observational studies 59 KRAS variant 59 methodologic 59 generalisable 59 psychotherapies 59 blinded randomized controlled 59 causal inference 59 rectal microbicide 59 cognitive behavioral therapies 59 placebo controlled multicenter 59 testable hypothesis 59 empiric therapy 59 STEP BD 59 Comparative effectiveness 59 CINQUIL 58 prospective multicentre 58 AVERROES 58 ongoing Phase IIIb 58 allergen avoidance 58 methodological limitations 58 ACCORD Eye 58 medicine EBM 58 GCP compliant 58 confirmatory clinical 58 colorectal carcinogenesis 58 developmental neurotoxicity 58 QTinno TM 58 nonpharmacologic 58 ASPIRE HIGHER 58 metabonomics 58 Confirmatory tests 58 unmeasured confounding 58 Subgroup analyzes 58 randomized controlled trials RCTs 58 convergent validity 58 biochemical profiling 58 Randomised controlled trials 58 causal inferences 58 Membrane proteins 57 NEUVENGE 57 Prof. Krainer 57 OpenNotes 57 PK PD modeling 57 CURRENT OASIS 7 57 BARI 2D 57 RCTs 57 poststroke depression 57 pulp metallic 57 topical NSAIDs 57 EchoCRT 57 intranasal corticosteroids 57 Bayesian statistical 57 thorough QT 57 Diamyd r vaccine 57 ALTTO 57 somatoform disorders 57 pharmacological therapies 57 biomarker identification 57 ToGA 57 non pharmacological interventions 57 generalizable 57 nonrandomized 57 psychodynamic therapy 57 Predictive modeling 57 MMP inhibitors 57 prognostically 57 NP2 Enkephalin 57 psychometrically sound 57 fight PI3K activation 57 QTinno 57 Zemplar Capsules 57 PREVENT IV 57 antiplatelet therapies 57 diagnostic modality 57 physiologic mechanisms 57 colon capsule endoscopy 57 routine neonatal circumcision 57 Observational studies 57 postmarketing surveillance 56 biostatistical analysis 56 IntroductionThe 56 pramlintide metreleptin combination 56 Randomized controlled 56 CURE AF 56 Multiple logistic regression 56 HIV tropism 56 MAGE A3 ASCI 56 Randomized clinical trials 56 BPG pouch machinery 56 postmarket surveillance 56 nonrandomized studies 56 Multiple linear regression 56 anti androgens 56 BIIR 56 unmeasured confounders 56 MGCD# clinical trials 56 lung cancer chemoprevention 56 ASCEND HF 56 metaanalysis 56 detecting diagnosing 56 CARE HF 56 pharmacologic intervention 56 immunological responses 56 rEEG 56 canakinumab 56 dose proportionality 56 Corus CAD 56 HF ACTION 56 Cytolin R 56 DACH platinum 56 biomolecular interactions 56 rigorously peer reviewed 56 pharmacological interventions 56 TriGrid 56 budesonide MMX Phase III 56 EEG abnormalities 56 INTERHEART study 56 Multivariate logistic regression 56 MediGene focuses 56 prospective longitudinal 56 BEXXAR therapeutic regimen 56 neuropsychological impairments 56 journal Psychological Bulletin 56 microarray gene expression 55 toxicogenomic 55 diagnosing ADHD 55 designated HVTN 55 CoQ# supplementation 55 ICD implantations 55 nanoscale phenomena 55 diagnosing autism 55 pivotal bioequivalence 55 Yeargin Allsopp 55 Cosmetic Ingredient Review 55 Cytolin ® 55 Evidence Therapeutic 55 imply causality 55 Flow cytometry 55 testosterone supplementation 55 nanotoxicology 55 Pagoclone 55 PLCO 55 residual confounding 55 subgroup analyzes 55 Mechanistic studies 55 TriRima 55 etiologic 55 pathogenetic mechanisms 55 tumor hypoxia 55 methodological rigor 55 functional gastrointestinal disorders 55 #F FDG PET 55 Nambu theories permeate 55 nonpharmacological 55 MTWA testing 55 PROCHYMAL 55 PROTEGE trial 55 oral anticoagulation 55 reboxetine 55 PET tracers 55 viral kinetics 55 infantile colic 55 tunnel Wethington 55 VADT 55 biological plausibility 55 scientifically invalid 55 atypical antipsychotic medications 55 periodontal infection 55 detect XMRV 55 STRIDE PD 55 Clinical Antipsychotic Trials 55 meta regression 55 CBLC# 55 PRIMO CABG 55 prognostic indicators 55 TCA grading 55 ENDEAVOR clinical 55 sirtuin activators 55 delipidation 55 Elevated triglycerides 55 multiplex assay 55 immunohistochemical 55 Vasogen Celacade 55 Longitudinal studies 55 biomarker validation 55 Mathematical modeling 55 neuropsychological impairment 55 observational cohort 55 hemoperfusion 55 ALLHAT 55 Dickersin 55 cobas HPV Test 55 pharmacogenetic tests 55 TLR antagonists 54 SIMPADICO 54 oncologic outcomes 54 epidemiologic studies 54 kidney urologic 54 samalizumab 54 enzyme immunoassay EIA 54 Randomized trials 54 ecotoxicological 54 TRILOGY ACS 54 Timothy Rebbeck 54 guideline concordant 54 meta analyzes 54 immunosuppressive regimens 54 prostate carcinogenesis 54 meta analytic 54 antitumoral 54 Vectibix monotherapy 54 EMPOWER TM 54 Still Wootan 54 Professor Ussher 54 bronchopulmonary dysplasia BPD 54 insertional mutagenesis 54 neratinib 54 methodologically 54 human microdosing 54 CaPSURE 54 PrEP trials 54 iPrEx study 54 atypical femur fractures 54 eprotirome 54 CYT# potent vascular disrupting 54 pharmacologic stress 54 antioxidant supplementation 54 impeach USADA 54 exonerate Kapoor 54 ERSPC 54 inferential statistics 54 synthetic lethality 54 NeuroStar TMS Therapy 54 MYTHOS trial 54 CALGB # [001] 54 imatinib resistance 54 NICE SUGAR 54 biopsychosocial model 54 Coronary angiography 54 APTIMA HPV 54 randomized controlled clinical trials 54 CyPath ® 54 staphylococcal vaccine 54 eTag assays 54 Afatinib 54 Daniel Rotrosen MD 54 antiepileptics 54 Poly ICLC 54 G. biloba 54 ToxCast ™ 54 formulate hypotheses 54 hematopoietic cancers 54 lipid lowering therapy 54 testable predictions 54 BRAF inhibitors 54 better childproof containers 54 Hair follicle 54 Sham acupuncture 54 ADME properties 54 Antibacterial soap 54 antiangiogenic therapy 54 GRI Guidelines 54 Intervention Trial GAIT 54 pharmacodynamic markers 54 optical biosensors 54 RE LY ® 54 Science Fund FWF 54 institute ITRI 54 Goldbeck Wood 54 Rheos System 54 BACcel 54 follicular adenoma 54 Prof. Rabani 54 inactivated influenza vaccines 54 teriflunomide 54 xxxi adverse tax 54 Cardiorespiratory fitness 54 bNAbs 54 optimal dosing 54 bioinformatic approaches 54 #HT#A partial agonist 54 multimodality imaging 54 hypersensitivity allergic reactions 54 Dr. Maraganore 54 cardio renal 54 Deutsches Arzteblatt International 54 Cristofanilli 54 my3KG 54 mechanistic studies 54 Abbott Trilipix 54 NO# [002] 54 demonstrated clinically meaningful 54 electromechanical coupling 54 chromium supplementation 54 vaginal microbicides 54 molecular determinants 54 PLCO trial 54 CB1 antagonists 54 AA Amyloidosis 54 RDTs 54 AIM HIGH 54 red clover isoflavones 54 ExTRACT TIMI 54 NATRECOR ® 54 antithrombotic therapy 54 favorable pharmacokinetic profile 54 trials RCTs 54 ragweed allergic 54 Cochrane reviewers 54 PROactive study 54 CardioFit 54 Uncontrolled hypertension 54 clinico pathological 54 Dr. von Herrath 53 investigational therapies 53 pharmacogenetic testing 53 linear pharmacokinetics 53 nutrient supplementation 53 Honda Asanuma 53 placebo controlled trials 53 microdose 53 Prenatal Alcohol 53 postmarketing adverse 53 HyQ 53 ICD therapy 53 antithrombotic agents 53 GeoVax vaccine 53 PITX2 methylation 53 statistical correlations 53 pharmacodynamic effects 53 masitinib 53 Michele Waslin director 53 methodological differences 53 NMR LipoProfile test 53 delafloxacin 53 aldosterone antagonists 53 Combination antiretroviral therapy 53 colonoscopic 53 trastuzumab emtansine T DM1 53 postexposure prophylaxis 53 microRNA profiling 53 bibliometrics 53 TARGIT 53 DAVANAT R exhibits 53 scientifically defensible 53 recurrent metastatic ovarian cancer 53 oral FTY# 53 antitumor effect 53 ticagrelor Brilinta 53 misused Teuber added 53 alpha7 NNR 53 ORAL Solo 53 generalizability 53 genotoxicity 53 precaution Wiehle 53 tests LDTs 53 atherosclerosis regression 53 fi ndings 53 LC#m# vaccine 53 attain statistical significance 53 pharmacotherapeutic 53 clevidipine 53 atherothrombotic disease 53 duplex ultrasonography 53 anti angiogenic drugs 53 HCV antibody 53 antiplatelet medications 53 Aggrastat ® tirofiban hydrochloride 53 Thorough QT 53 ACRIN 53 environmental toxicants 53 Dr. Fombonne 53 retrospective observational 53 skin sterol 53 BioSilicon 53 opioid antagonists 53 YONDELIS 53 PECARN 53 Francesca Bravi 53 Rh proteins 53 pharmacokinetic characteristics 53 Tyrima 53 inhaled nitric oxide 53 OncoVEX GM CSF 53 renal denervation 53 carbohydrate polymers 53 hawthorn extract 53 Dr. Gulfo 53 randomized controlled trials 53 eC SSRS 53 Tanner Steidel 53 behavioral interventions 53 thoracoscopic lobectomy 53 pharmacotherapies 53 NSDUH 53 scientifically flawed 53 ADAGIO study 53 pharmacoeconomic 53 pure fructose 53 treating enlarged prostates 53 Towering scholar 53 intravenous bisphosphonates 53 biologic pathways 53 ELCAP 53 EXPLORE Xa 53 Dr. Roehrborn 53 mechanistic explanation 53 clinical pharmacology studies 53 HORIZONS AMI trial 53 APTIMA HPV assay 53 Vaxfectin TM 53 scientifically rigorous 53 ganaxolone 53 SPARCL 53 antidepressive 53 empirically testable 53 radiographic outcomes 53 legitimate penological objectives 53 chemoprevention trials 53 Epidemiologic studies 53 NESARC 53 Reproducibility 53 National Guideline Clearinghouse 53 stratifying patients 53 conditional logistic regression 53 GI motility disorders 53 Dr. Aman Buzdar 53 HIVNET 53 genotype phenotype 53 ToxCast 53 multicenter randomized clinical 53 coinfected patients 53 psychotherapeutic interventions 53 HPV genotyping 53 Outpatient Setting 53 HYVET 53 Intervention Effectiveness CATIE 53 NUCYNTA ™ 53 meta analysis pooling 53 empiric 53 conventional angiography 53 SCD HeFT 53 pharmacological approaches 53 ONTARGET 53 econometric analyzes 53 BCIRG 53 IPTi 53 pharmacodynamic parameters 53 Cognitive behavioral 53 reducing sodium intake 53 Heavy snorers 53 pharmacologic treatments 53 Mevacor OTC 53 pain palliation 53 Strengths Near 53 validating biomarkers 53 intracranial stenosis 53 Quantitative EEG 53 oncological outcomes 53 scientifically valid 53 BEXXAR Therapeutic Regimen 53 randomized trials 53 interinstitutional 53 carotid artery stenting 53 diagnosable mental disorders 53 chlamydial infection 53 BHGI 53 KIF6 carriers 53 mTOR kinase 53 mean ± SEM 53 ELISPOT 53 EEG biofeedback 53 SOCE 53 adipose derived stem cell 53 CareEngine System 53 Alpha Tocopherol Beta Carotene 53 predictive validity 53 ICD implantation 53 miRview ™ tests 53 florbetaben 53 antiangiogenic agents 53 psychopharmacological 53 DNAwithPap TM Test 53 atherothrombotic 53 macrolide antibiotics 53 metabolomic profiling 53 ADMIRE HF 53 androgen depletion 53 primate cognition 53 clinically meaningful endpoint 53 randomized clinical trials 53 number NCT# ClinicalTrials.gov 53 neuroregenerative 53 Education Next PEPG 52 dietary modification 52 vitro dissolution 52 AChE inhibitors 52 Cardiopulmonary bypass 52 subcutaneous PRO 52 empirical 52 Non inferiority 52 ACOSOG Z# 52 TNF antagonist 52 fusion enhancers 52 Digital Mammographic Imaging 52 chemopreventive agents 52 scientifi c 52 Tasigna prolongs 52 deadlier outbreaks 52 PharmaVOICE editors 52 pharmacokinetic pharmacodynamic 52 microwell plate 52 Lou Sessinger column 52 EquiTrend ® 52 Farmstead Telephone 52 adjuvant therapies 52 recurrent miscarriage 52 SYMMETRY trial 52 androgen depletion therapy 52 PLX cells 52 antibiotic regimens 52 recurrent glioma 52 quantitive 52 RESOLUTE clinical 52 Lofexidine 52 microRNA biomarkers 52 randomized discontinuation 52 APEX AMI 52 TAXUS VI 52 semistructured interviews 52 biopsychosocial 52 Hepatocellular Carcinoma HCC 52 Proximate cause 52 quantative 52 EGS# 52 dietary antioxidants 52 Cardiotoxicity 52 FTIs 52 FENO 52 STICH trial 52 ImmunoVEX HSV2 52 Dialysis Outcomes 52 serologic 52 quantitative gene expression 52 Cochrane Systematic Review 52 Immune Tolerance Network 52 Pharmacokinetic parameters 52 plasminogen activators 52 OMAPRO 52 Wisconsin Sleep Cohort 52 Hedgehog inhibitor 52 SYNTAX trial 52 prospective observational cohort 52 OHR/AVR# 52 silico modeling 52 Multicenter Automatic Defibrillator Implantation 52 fetal oxygen saturation 52 ANCHOR trial 52 Tollerud committee 52 pharmacokinetic interactions 52 Dr. Chenchen Wang 52 Descriptive statistics 52 Visit www.usgbc.org 52 LLLT 52 DAPT Study 52 statin medications 52 ThermoDox ® clinical 52 ROCHESTER Minn. Mayo Clinic 52 Coremetrics Benchmark 52 CHAMPION PLATFORM 52 catheter ablations 52 RIO Lipids 52 oral prednisolone 52 medavis 52 nanocomposite material 52 Guava EasyCD4 52 INTERPHONE 52 periprocedural MI 52 Boston DbTechNo Results 52 intensive lipid lowering 52 http:/www.emergingstockreport.com 52 Phase #/#a 52 virotherapy 52 Vimpat R 52 Prostate AdenoCarcinoma Treatment 52 journal Gynecologic Oncology 52 Texts emails 52 Artemisinin Combination Therapies ACTs 52 preclinically 52 econometric techniques 52 HER2 expression 52 creatine supplementation 52 dietary interventions 52 metastatic RCC 52 lung cancer NSCLC 52 XRF readings 52 ImmuKnow assay 52 routine episiotomy 52 surface plasmon resonance SPR 52 immunochemical fecal occult 52 percutaneous cryoablation 52 asthma immunotherapeutic 52 Dr. Yair Lotan 52 plasma pharmacokinetics 52 curative therapy 52 Zolopa 52 CHAMPION PCI 52 pathogenic mechanisms 52 Computational biology 52 cytochrome P# inhibition 52 bioequivalency 52 Vascugel TM 52 pathophysiological mechanisms 52 airborne pollutant 52 Dr. Sharonne Hayes 52 iPrEx 52 pix Hacking 52 CAMMS# 52 journal Palaios 52 nonvaccine 52 psychotherapeutic treatments 52 Phase IIIB IV 52 Pa. Chaka Fattah 52 ALN RSV program 52 BACcel ™ system 52 antiresorptive 52 Okunieff 52 NCCN guidelines 52 surrogate endpoint 52 renin inhibition 52 electrophysiologic 52 spectroscopic technique 52 NeuroFlo 52 chronic bilirubin encephalopathy 52 Chlamydia trachomatis infection 52 differential gene expression 52 galiximab 52 Society ILADS 52 Cerashield 52 TOLAMBA 52 toxicologic 52 preclinical efficacy 52 Dyax phage display 52 Associated Press Ipos poll 52 Src inhibitors 52 Carotid Revascularization Endarterectomy vs. 52 IQWiG 52 eco toxicological 52 lymphatic mapping 52 Clinicaltrials.gov 52 ORMDL3 52 proteomic biomarkers 52 antitumour activity 52 malignant mesothelioma Alfacell 52 genomic alterations 52 myopathy rhabdomyolysis 52 PRESEPT 52 Gad Getz 52 Therapeutic antibodies 52 stochastic simulation 52 scientific.thomson.com 52 placebo controlled studies 52 clinicopathologic 52 S. maltophilia 52 probiotic supplementation 52 Bergenstal 52 enzyme kinetics 52 immune modulatory 52 logistic regression models 52 flavopiridol 52 HIFU therapy 52 EDEMA3 trial 52 Simin Nikbin Meydani 52 homocysteine lowering 52 adjuvanted vaccines 52 APPRAISE 52 trastuzumab DM1 T DM1 52 quantifications 52 cardiac perfusion 52 prospective randomized controlled 52 tumor subtypes 52 EMPOWER ™ 52 noninferiority 52 Berkelhamer 52 TQT studies 52 antitumour 52 carotid bruit 52 Psychometric tests 52 prostate cancer CaP 52 Kattlove 52 Mantel Haenszel 52 ELISpot 52 ProUroScan prostate imaging 52 pharmacological treatments 52 Notch inhibitors 52 IV bisphosphonates 52 Postmarket 52 EndoTAG TM 52 antiplatelet drugs 52 bioaerosol 52 pelvic malignancies 52 non dispersive infrared 52 viral tropism 52 UC CEIN 51 AF ablation procedures 51 convenient dosing regimens 51 neuroimaging studies 51 EFQM Excellence Model 51 epidemiologically 51 VentureOne proprietary 51 Sensitivity analyzes 51 biomedically 51 venous thromboembolism VTE prophylaxis 51 CCR5 receptor antagonist 51 neuropsychological assessment 51 Myriad Flurizan 51 stem cell transplantations 51 BEZ# 51 Val HeFT 51 www.ClinicalTrials.gov 51 authors hypothesized 51 journal Chemical Senses 51 multicenter Phase II 51 radiolabeled TM# 51 OvaRex MAb 51 AVADO 51 Tobias Kurth 51 multiplex biomarker 51 Ovarian Cancer Screening 51 thromboprophylaxis 51 organophosphate exposure 51 TransVax ™ 51 penile vaginal penetration 51 serum lipid 51 Balloon angioplasty 51 perfusion CT 51 Michael Leitzmann 51 OLYMPIA registry 51 enterotypes 51 cediranib 51 thrombotic complications 51 radiofrequency catheter ablation 51 adrenergic regulation 51 relapsed MM 51 molecular biomarker 51 spokeswoman Tisha Petteway 51 symptomatic pulmonary embolism 51 Gen. Tito Karnavian 51 HER2 positive cancers 51 KN excels 51 HCV protease inhibitors 51 stratospheric sulfates proposal 51 multicentric 51 GYTS 51 postapproval 51 epigenetic therapies 51 serum biomarkers 51 Frobell 51 PM#.# exposure 51 Alan Dangour 51 thromboembolic disease 51 ginkgo extract 51 UREX process 51 NADiA 51 biomarker discovery validation 51 bibliometric 51 nutrigenomic 51 HER2 overexpression 51 Tryton stent 51 organometallic compounds 51 Antioxidant supplements 51 Erik Ostensoe P. Geo 51 β blockers 51 vitro molecular diagnostic 51 patriotism Gration 51 Teriflunomide 51 nanoparticle toxicity 51 leukotriene receptor antagonists 51 vitro ADME 51 Kaplan Meier curve 51 neurosensory 51 multidose 51 Vidofludimus 51 anticoagulant reversing agent 51 IBMT 51 carotid artery stenting CAS 51 RE LY trial 51 Vertos II 51 inferences therefrom 51 cytoreductive nephrectomy 51 non selective NSAIDs 51 Evidence Therapeutic study 51 Oral NKTR 51 predictive toxicology 51 eprodisate Fibrillex TM 51 rEEG ® 51 Dr. Tashkin 51 cordycepin 51 urodynamic studies 51 PV module efficiencies 51 UHCMC 51 HIF PH inhibitors 51 NUCYNTA R 51 CCR5 inhibitor 51 DSM IV diagnoses 51 Genetic predisposition 51 inecalcitol 51 biologic DMARDs 51 nanoproducts 51 named RIGOR 51 underlying molecular mechanisms 51 HPTN 51 P. vivax malaria 51 MGd 51 LHRH antagonists 51 peer reviewed 51 worthwhile Schwehm 51 fermentable carbohydrates 51 reproducible measurements 51 blinded randomized placebo controlled 51 Vaxfectin R adjuvant 51 triple nucleoside regimen 51 microbiology immunology epidemiology 51 externally validated 51 Allovectin 7 ® 51 methodological shortcomings 51 hoax Alderden 51 oral talactoferrin 51 chronic prostatitis chronic 51 radezolid 51 CaPre TM 51 hoFH patients 51 vitamin D inadequacy 51 Elocalcitol 51 journal Resuscitation 51 Hyperbaric Oxygen Therapy HBOT 51 oral malodor 51 urodynamic 51 Newschaffer 51 NATRECOR R 51 late onset hypogonadism 51 probabilistic reasoning 51 Screening Trial DMIST 51 Dr. Cliby 51 macrolide antibiotic 51 EndoTAG TM -1 51 pharmacological therapy 51 testable theories 51 Nasdaq ONXX today 51 unmeasured factors 51 maximally tolerated dose 51 spirometric 51 psychopharmacologic 51 commonly prescribed antidepressants 51 Jack Pirozzolo 51 GVAX Pancreas Vaccine 51 Arch Surg 51 HDL Selective Delipidation 51 radionuclide therapy 51 objectively verifiable 51 transrectal ultrasound 51 RoACTEMRA 51 pharmacologically relevant 51 liposome formulations 51 CardioBip 51 microbiologically evaluable 51 VDAs 51 recombinant PSMA vaccine 51 Tumor Response 51 symptomatic paroxysmal AF 51 Myerburg 51 MALDI-TOF/TOF 51 avosentan 51 Diabetes ACCORD 51 biocatalytic 51 psychobiological 51 Resolute DES 51 airway responsiveness 51 String theory 51 Francesca Dominici 51 DeWyze raspy tone 51 recombinant interferon 51 ischemic tissues 51 coxibs 51 orofacial clefts 51 clinically relevant 51 synthetic retinoid 51 Nanostructured materials 51 Understanding Universal BCAR 51 ovarian suppression 51 ALK inhibitors 51 photochemical processes 51 randomized controlled clinical 51 etiological 51 MTP inhibitors 51 StockPickReport.Com ranks stocks 51 scientific substantiation 51 needleless connectors 51 QTinno ™ 51 Dr. Douglas Diekema 51 Synchrotron radiation 51 metabolite identification 51 SA Asgi SA 51 cobiprostone 51 presymptomatic 51 judicially manageable 51 vivo assays 51 Lp PLA 2 51 conjoint analysis 51 pharmacokinetic equivalence 51 boards IRBs 51 SiMoA 51 radiation dosimetry 51 lomitapide 51 prophylactic anticoagulation 51 genomic biomarker 51 kinase profiling 51 Archimedes Model 51 internalizing disorders 51 telomerase inhibition 51 PHEMCE 51 visit www.tia.org 51 pharmacodynamic endpoints 51 Phase IIb III 51 semistructured 51 BioMatrix TM 51 exploratory endpoints 51 DuPont http:/www.dupont.com 51 VITAL Trial 51 MassTag PCR 51 familial clustering 51 PKC isozymes 51 dose escalation phase 51 Pebble Beach Calf 51 SuperMedia specializes 51 Cinzia Marano 51 CGEMS 51 adjuvant systemic 51 Protein Structure Initiative 51 Bracketed figures 51 certifying blowout preventers 51 anything Chachoute 51 varicoceles 51 multivariate regression 51 immunotherapeutic approaches 51 abnormal lipid 51 #beta estradiol 51 FDCC Scanner 51 cancer chemoprevention 51 genetic loci 51 HuLuc# 51 Notified Bodies 51 ChainLink 51 Roxana Mehran MD 51 mTOR inhibition 51 invasive lobular carcinoma 51 Amy Abernethy 51 Rasenick 51 curability 51 Arman Sidhu ss . 51 Molnar Szakacs 51 homoeopathic remedies 51 DIRECTORS OF CAPITAL CORP. 51 Tony Wyss Coray 51 toxicological studies 51 phase IIIb 51 sustained virological response 51 methotrexate therapy 51 Rumbeiha 51 Relieve Depression 51 gemifloxacin 51 Optical coherence tomography 51 attacks Akawu 51 elevated CRP 51 relapsed SCLC 51 indibulin 51 noscapine